Trials / Terminated
TerminatedNCT00779285
Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)
Cardiac Safety Profile of Caelyx Therapy in Anthracyclin Pretreated Metastatic Breast Cancer Patients.
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with metastatic breast cancer who have previously received chemotherapy with anthracyclines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Liposomal Doxorubicin | Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator. |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2008-10-24
- Last updated
- 2015-07-14
- Results posted
- 2010-03-10
Source: ClinicalTrials.gov record NCT00779285. Inclusion in this directory is not an endorsement.